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Abstract
Background: The aim of this study was to systematically review the content validity and measurement properties
of all physical function (PF) scales which are currently validated for use with patients with rheumatoid arthritis (RA).
Methods: Systematic literature searches were performed in the Scopus and PubMed databases to identify articles
on the development or psychometric evaluation of PF scales for patients with RA. The content validity of included
scales was evaluated by linking their items to the International Classification of Functioning Disability and Health
(ICF). Furthermore, available evidence of the reliability, validity, responsiveness, and interpretability of the included
scales was rated according to published quality criteria.
Results: The search identified 26 questionnaires with PF scales. Ten questionnaires were rated to have adequate
content validity. Construct validity, internal consistency, test-retest reliability and responsiveness was rated
favourably for respectively 15, 11, 5, and 6 of the investigated scales. Information about the absolute measurement
error and minimal important change scores were rarely reported.
Conclusion: Based on this literature review, the disease-specificHAQ and the generic SF-36 can currently be most
confidently recommended to measure PF in RA for most research purposes. The HAQ, however, was frequently
associated with considerable ceiling effects while the SF-36 has limited content coverage. Alternative scales that
might be better suited for specific research purposes are identified along with future directions for research.
Keywords: Physical function, disability, rheumatoid arthritis, psychometric, validity, reliability, responsiveness, mea-
surement properties
Background
Patients’ assessment of physical function (PF) is a core
outcome domain of disease status in rheumatoid arthri-
tis (RA)[1,2]. Physical function scales are used in the
majority of clinical trials to assess the effectiveness of
treatment and have become established instruments for
assessing health outcomes in clinical practice and obser-
vational studies as well [3-5].
A number of efforts have currently been undertaken
to compare the variety of disease-specific and generic
PF scales that have been validated for use in patients
with RA over the years [6-11]. However, previous efforts
have been limited to descriptive reviews of well-known
instruments or non-systematic selections of the available
literature on their measurement properties. To date,
there are no comprehensive studies available that sys-
tematically evaluate the evidence for the quality of the
measurement properties of all PF scales that are vali-
dated for patients with RA. Furthermore, until recently
there was no comprehensive conceptual framework
available to define physical function in RA and with
which to judge the relevance and comprehensiveness of
the items of PF scales. Therefore, content validity could
only be evaluated indirectly in previous efforts, for
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example by evaluating whether patients were included in
the item selection process. Currently, the International
Classification of Functioning, disability and Health (ICF)
provides a comprehensive frame of reference, which
allows the relevance and comprehensiveness of the
items of PF scales to be examined directly by linking
them to their respective ICF codes. Within the ICF clas-
sification, the ‘activity’ dimension constitutesthe indivi-
dual’s perspective on functioning and is defined as
‘difficulties an individual may have in executing activities
[12]. This dimension consists of the chapters domestic
life, self-care and mobility, which respectively coincide
with (instrumental) activities of daily living (IADL &
ADL) and mobility which are traditionally used terms in
the literature on physical functioning [13].
The most relevant ICF categories for a particular con-
dition are summarized in a core set. The ICF Core Set
for RA is a list of the ICF categories, which represent
the typical functional problems experienced by patients
with RA [14]. The outcome measures in rheumatology
(OMERACT) group accepts the ICF core set for RA as
the best currently available external standard of func-
tioning and recognizes its utility for assessing the con-
tent validity of existing measurement instruments [15].
The aim of this study was to systematically review the
content validity and measurement properties of all PF
scales that have been validated for use in patients with
RA, by linking their content to the ICF and to appraise
the currently available evidence of the quality of their
measurement properties in order to offer recommenda-
tions for the use of PF scales for various purposes and
settings.
Methods
Study selection
An extensive literature search was conducted to retrieve
all relevant articles related to the psychometric evalua-
tion of PF scales in RA. A validated and sensitive search
strategy for finding studies on measurement properties
of patient-reported outcomes (PROs) was followed to
design the search strings [16] and applied to the Scopus
(1972-2010) and PubMed databases (1975-2010) in Jan-
uary 2011. This search strategy consists of four sets of
independent searches that are later merged. The first
search contains various synonyms of the construct of
interest (i.e., physical function). The second search con-
tains search terms for the population of interest (i.e., RA
patients). The third search contains the validated and
sensitive filter for the identification of studies investigat-
ing measurement properties of health-related PROs and
the fourth search contains an exclusion filter. For more
details about the content of the filters we refer to Ter-
wee et al [16].The full search strings used in PubMed
are available from the corresponding author.
Two reviewers (MOV and PTK) independently
screened the titles and abstracts of the search results to
identify potentially relevant studies. Studies were eligible
if they were published in English, the main focus of the
article was the development or psychometric evaluation
of a questionnaire, at least part of the study population
consisted of patients with RA, and the questionnaire
was intended for use in adults. Final decisions on inclu-
sion of studies in the review were made by consensus
after both reviewers read all full-text articles that were
deemed potentially relevant by either reviewer
individually.
Questionnaires were retained for further review if they
contained at least one scale addressing an aspect of
overall PF (i.e., the ability to carry out basic or instru-
mental activities of daily living or mobility tasks), and
were not limited to assessing the functioning of specific
joints or limbs. Given the difficulty of assessing the
quality of the applied translation procedures and the
equivalence of translated versions of the questionnaires,
only studies examining the measurement properties of
the original language version were included. In case the
original language of a questionnaire is spoken as the
majority language in other countries, studies from those
countries were considered to have used the original ver-
sion, unless stated otherwise in the article. Finally,
because the quality criteria used in this study require at
least 50 patients per analysis to be eligible for rating,
studies were included if analyses were reported for at
least 50 patients with RA [17]. Furthermore, in case
patient groups with various diseases were studied that
were not analysed per patient group, studies were
included if the study population contained at least 50%
patients with RA, as has been done in similar, previous
systematic reviews [18].
To ensure that all relevant studies were retrieved, a
second series of searches was performed with the names
of the retained questionnaires as search terms in addi-
tion to the words “rheumatoid arthritis” and references
of included studies and studies citing the original article
were manually searched using Scopus citation tracker.
Lastly, search results were verified against previous non-
systematic review articles of PF scales [6-11].
The full name of each retained questionnaire, the year
of its development, and the language it was developed
in were extracted, as well as the names of all scales rele-
vant to the assessment of PF and their respective num-
ber of items. The consensus based standards for the
selection of health status measurement instruments
(COSMIN) checklist [19] was used to identify and
extract information on measurement properties that are
considered relevant for PROs. The COSMIN checklist
was developed in a Delphi study among 43 experts in
the field of health outcome measurement and contains
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standards for which measurement properties are most
relevant to HR-PROs and standards for how these mea-
surement properties should be evaluated in terms of
study design and statistical analysis. Two reviewers
(MOV & PTK) independently scored the checklist
according to instructions in the manual for all included
studies. Consensus about the ratings was reached by dis-
cussion. The quality of the measurement properties was
rated according to quality criteria that were proposed
for the COSMIN checklist [17]. An overview of all data
relevant to the rated measurement properties is available
in the supplementary material (additional File 1, addi-
tional File 2 & Additional File 3.).
Validity
Validity refers to the degree to which a scale measures
what it sets out to measure [20]. Since no gold standard
exists for patient reported physical function, scales
should demonstrate content and construct validity [21].
Content validity should be assessed by making judg-
ments about the relevance and the comprehensiveness
of the items for assessing physical functioning of
patients with RA [19]. The relevance of a scale was
rated positively if all items of a scale could be linked to
ICF codes that are included in the ICF core set for RA
and belong to one of the three chapters of the activity
domain: self-care, domestic life or mobility. A scale was
considered to measure PF comprehensively in case its
content covers all three chapters of the activity dimen-
sion of the ICF. For this analysis all items of the
included scales were linked to the ICF according to
peer-reviewd linking rules [22].
Construct validity refers to the extent to which scores
on a questionnaire relate to other measures in a manner
that is consistent with theoretically derived hypotheses
concerning the constructs that are measured [23]. How-
ever, in the included studies, hypotheses were rarely spe-
cified a priori when the construct validity of a scale was
examined. This lack of hypotheses about the magnitude
of expected relationships with clinical or other PROs
limits interpretation of the results. Based on text book
recommendations, included studies that did specify
hypotheses and previous experience with validating PF
scales, the following set of hypotheses was specified
[24-33]: A PF scale with adequate construct validity
should correlate most strongly with other PF instru-
ments, it should correlate second most strongly with
other patient-reported measures of physical aspects of
health (e.g., pain or the physical component score of the
SF-36). PRO measures of non-physical aspects of health
and clinical outcome measures (e.g., tender and swollen
joint counts) should be less strongly related to the PF
scale than the previous measures. Finally, we would
expect the least strong correlations with (biological) pro-
cess measures of disease activity. With respect to the
absolute magnitude of correlations, a valid measure of
PF was expected to correlate strongly (r > 0.60) with
other measures of PF and measures of other aspects of
physical health and moderately (0.30 <r < 0.60) with
clinical outcome measures and patient reported non-
physical aspects of health. Following the quality criteria
of Terwee et al for a positive rating for construct valid-
ity [17], at least 75% of hypotheses should be confirmed
and, in case a scale was validated against other estab-
lished (multi-item) self-reported measures of PF, we
considered it to be vital that the correlation was strong
(r > 0.60).
Internal consistency
Scales that are internally consistent are made up of
items that all measure the same concept and conse-
quently produce correlated scores. When correlations
among items are too high, however, redundant content
is indicated [17]. Questionnaires received a positive rat-
ing for internal consistency if factor analysis indicated
the homogeneity of each relevant scale in a sufficiently
large sample (≥5 patients for every item in the analysis)
and Cronbach’s a was ≥0.70, but ≤0.95 for each relevant
scale or the person separation index (or person reliabil-
ity) was ≥0.70 if Rasch analysis was applied [17].
Reproducibility
This concerns the degree to which repeated measure-
ments in stable patients provide similar results. We
assessed agreement and test-retest reliability. Studying
agreement is important to detect systematic differences
between measurements and to establish how much
scores of individual patients can be expected to vary
from one occasion to the next when there is no real
change in functional status [34,35]. The standard error
of measurement (SEM) or limits of agreement (LOA)
[34] were considered to be adequate parameters of
agreement. Agreement was considered acceptable if the
minimal important change (MIC, see under interpret-
ability) was greater than the smallest detectable change,
which can be calculated from the SEM, or if the MIC
was outside the LOA. Because the MIC was not com-
monly reported, we also gave a positive rating in case
the authors provided convincing arguments that agree-
ment was acceptable.
Scales that are reliable, reproducibly distinguish
between patients with unchanged levels of PF, despite
measurement error. A positive rating for test-retest
reliability was given if the intraclass correlation coeffi-
cient (ICC) for continuous measures or weighted kappa
for categorical measures was ≥0.70 in a sample of at
least 50 stable patients over a period of one to six weeks
[17].
Responsiveness
The ability of a questionnaire to detect clinically mean-
ingful changes over time, even if those changes are
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small, is called responsiveness [36]. Measuring change
over the course of a therapeutic intervention with
known effectiveness was considered to be the most
appropriate technique for assessing responsiveness of PF
scales [37,38]. A positive rating was given when ade-
quate statistics, such as the standardized effect size or
the standardized response mean, indicated a treatment
effect of at least 0.30, which constitutes a moderate
magnitude according to Cohen [39]. Because observed
treatment effects depend critically on contextual ele-
ments such as the treatment used, the disease severity
of the study sample, and the employed time frame, an
adequate description of these elements was required for
a positive rating as well.
Interpretability
Finally, it is important that clinicians and policy makers
are able to assign qualitative meaning to questionnaire
scores. Three aspects of interpretability were given indivi-
dual ratings. First, minimally important change (MIC)
scores should be documented. The MIC is the smallest
change in score perceived to be important. Given that
PRO measurement is inherently about the patients’ per-
spective and that there is no objective gold standard for
adequate changes in functional status, anchor-based tech-
niques where patients rated the amount of change they
experienced on a transition question, were considered to
be appropriate. A positive rating was given if an adequate
external indicator was used to categorize patients accord-
ing to change status, the indicators were adequately
described, and the relationship of the indicator with the
questionnaire was sufficiently documented [37].
Secondly, substantial floor and ceiling effects should be
absent. A large percentage of patients at the floor or ceil-
ing of a measure limits the interpretability of change
scores because further deterioration or improvement in
functional status may occur but cannot be detected by the
scale. A positive rating was given when ≤15% of patients
either scored the lowest or highest possible score [17].
Finally, presenting scale scores for relevant subgroups
of patients or before and after treatment and relating
questionnaire scores to other outcome measures facili-
tates interpretability. A positive rating was given if at
least two of the following types of information were pre-
sented: means and standard deviations before and after
treatment with proven effectiveness, differences in
scores between relevant groups, relating scores to
patient’s global ratings of change in disability or present-
ing information on the relationship of scores to other
well-known measures of disability.
Results
Selection of studies
The main search yielded a total of 3257 hits, of which
306 studies met the inclusion criteria and were retrieved
for review. Of the 110 questionnaires that were psycho-
metrically evaluated in the studies, 65 did not contain a
(separate) PF scale and 18 questionnaires were limited
to assessing the functioning of specific limbs or joints.
The 51 studies identified by the main search that exam-
ined the measurement properties of the original lan-
guage version of one of the 26 retained questionnaires
were kept for review. Manual searching and reference
checking resulted in the identification of 3 additional
studies that were reviewed as well.
Description of the questionnaires
Table 1 summarizes the characteristics of the included
questionnaires. In case a questionnaire was originally
developed for use in patient groups other than RA, the
original article about the development of the question-
naire was consulted. For descriptive purposes, question-
naires were grouped as generic (7 questionnaires) in
case they were developed for use in diverse or general
populations or disease-specific (19 questionnaires) when
the questionnaire was developed for use in arthritic
populations, according to the original articles.
Measurement properties
Ratings of the measurement properties are presented in
table 2. Each measurement property is qualified as ade-
quate with good methodological quality (+), indetermi-
nate because of doubtful methodological quality (0), or
inadequate with good methodological quality (-), Ques-
tion marks indicate insufficient information about an
aspect.
Content validity
In total, only 30 out of 591 (5%) concepts that were
identified in the items could not be linked to the ICF.
The vast majority of concepts were linked to the chap-
ters Mobility (47%), Self-care (23%) or Domestic life
(10%). Questionnaires were rated for relevance and
comprehensiveness.
Of the generic questionnaires, the GARS, MHIQ,
NHP and SF-36 were rated positively for relevance
because all their PF items could be linked to one of
the ICF chapters mobility, self-care or domestic life
(see table 2). Three generic questionnaires were rated
negatively for relevance. The BI and SIP contain items
related to faecal and urinary incontinence (ICF codes
B5253 and B6202), and an item about transferring one-
self (D420), which is not part of the ICF core set for
RA. The SIP also contains an item that was linked ves-
tibular function of balance (B2351), which belongs to
the domain body functions. The WHODAS-II contains
an item that was linked to the general tasks and
demands category (D2302) from chapter 2, general
tasks and demands and an item linked to remunerative
employment (D850).
Oude Voshaar et al. Health and Quality of Life Outcomes 2011, 9:99
http://www.hqlo.com/content/9/1/99
Page 4 of 13
Thirteen disease-specific questionnaires were rated
positively for relevance because all their respective PF
items could be linked to mobility, self-care or domestic
life categories featuring in the core set. Five disease-spe-
cific questionnaires were rated negatively for relevance.
SIP-RA contains an item that was linked to vestibular
function of balance (B2351), which belongs to the
domain body functions and an item linked to the cate-
gory mobility of a single joint (B7101) from the body
functions chapter. The CSHQ-RA contains an item
linked to mobility of a single joint(B7101) as well and
multiple items linked to sensory of pain (B280) in its
dexterity and mobility scale and one item linked to
sleep function (B134). The CSSRD-FAS contains an
Table 1 Descriptive information of included questionnaires
Questionnaire Year Original
language
Target population Relevant scales (# of items)
Generic
questionnaires
BI 1955 English (US) Chronic illnesses/
Rehabilitation patients
Barthel Index (10)
GARS 1993 Dutch Older patients Activities of daily living (8), Instrumental activities of daily living (11)
MHIQ 1976 English (US) Free living populations Physical function index (24)
NHP 1980 English (UK) General population Physical Mobility (8)
SF-36 1992 English (US) General population Physical functioning (10)
SIP 1975 English (US) General sick population Ambulation (12), Body care and movement (23), Mobility (10)
WHODAS-
II
1999 Multilingual General population Getting Around (5), Self-care (4), Life activities (8)
Diseases specific Questionnaires
FSI 1980 English (US) Osteoarthritis Mobility (3), Personal care (4), Home chores (4), Hand activities (3)
AIMS 1979 English (US) Arthritic conditions Mobility (4), Physical activity (5), Activities of daily living (4), Dexterity (5)
Short AIMS 1991 English (US) Arthritic conditions Mobility (2), Physical activity (3), Activities of daily living (2), Dexterity (3),
Household activities (4)
Shortened
AIMS
1989 English (US) Arthritic conditions Mobility (2), Physical activity (2), Activities of daily Living (2), Dexterity (2),
Household activities (2)
AIMS2 1991 English (US) Arthritic conditions Mobility (5), Walking and bending (5), Hand and finger function (5), Arm
function (5), Self-care (4), Household (4)
AIMS2-SF 1993 French Arthritic conditions Physical component (12)
CSHQ-RA 2006 English (US) Rheumatoid arthritis Dexterity (7), Mobility (8)
CSHQ-RA,
revised
2006 English (US) Rheumatoid arthritis Dexterity (6), Mobility (6)
CSSRD-FAS 1995 English (US) Rheumatoid arthritis Personal care (14). Mobility (1), Transfer (1) Work/play (18)
FFbH 1990 German Polyarthritic conditions Funktions fragenbogen (18)
HAQ 1980 English (US) Arthritic conditions Disability index (20)
HAQ-II 2004 English (US) Arthritic conditions Disability index (10)
MDHAQ
(10-ADL)
1983 English (US) Arthritic conditions Disability index (10)
MDHAQ
(14-ADL)
2005 English (US) Arthritic conditions Disability index (14)
MHAQ 1983 English (US) Arthritic conditions Disability index (8)
ROAD 2005 Italian Early arthritis Upper extremity function (5), Lower extremity function (4), Activities of daily
living/work (3)
IRGL 1990 Dutch Arthritic conditions Mobility (7), Self-care (8)
TFCQ 1982 English (US) Rheumatoid arthritis Mobility (4), Personal care (4), Arm/hand functions (7), Work/play (4)
SIP-RA 1993 Swedish Rheumatoid arthritis Body care and movement (14), Mobility (5)
BI = Barthel Index, GARS = Groningen Activity Restriction Scale, MHIQ = McMaster Health Index Questionnaire, NHP = Nottingham Health Profile, SF-36 = MOS 36
item short form Health survey, WHODAS-II = World Health Organization Disability Schedule-II, FSI = Functional Status Index, AIMS = Arthritis Impact Measurement
Scales, Short AIMS = Short Arthritis Impact Measurement Scales, Shortened AIMS = Shortened Arthritis Impact Measurement Scales, AIMS2 = Arthritis Impact
Measurement Scales 2, CSHQ-RA = Cedars-Sinai Health Related Quality of Life for Rheumatoid Arthritis instrument, CSHQ-RA Revised = Cedars-Sinai Health
Related Quality of Life for Rheumatoid Arthritis instrument Revised, CSSRD-FAS-FAS = Cooperative Systematic Studies for Rheumatic Diseases group Functional
Assessment Survey, FFbH = Funktionsfragenbogen, Hannover, MDHAq = Multidimensional Health Assessment Questionnaire, M-HAQ = Modified Health
Assessment Questionnaire, HAQ = Health Assessment Questionnaire, HAQ-II = Health Assessment Questionnaire II, ROAD = Recent Onset Arthritis Disability
Questionnaire, SIP-RA = Sickness Impact Profile for Rheumatoid Arthritis, TFCQ = Toronto Functional Capacity Questionnaire IRGL = Impact van Reuma op
Gezondheid en Leven.
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item linked to remunerative employment (D850). The
AIMS contains an item related to carrying out daily rou-
tine (D2308) and the ROAD contains an item that was
linked to basic interpersonal interactions (D710).
In the analysis of comprehensiveness, nine question-
naires, four of which generic, were rated negatively (see
table 2). All negatively rated questionnaires lack items
assessing the domestic life chapter of the ICF (i.e.,
IADL). Overall, only ten questionnaires received favor-
able ratings for both aspects of content validity, indicat-
ing that all their items are relevant to the assessment of
PF of patients with RA and all three relevant ICF chap-
ters are measured by the items making up the scale.
Construct validity
Of the included generic scales, the construct validity of
the WHODAS-II could not be rated because only the
construct validity of the total score was investigated,
which also includes scales measuring non-physical
aspects of quality of life. The MHIQ was rated favour-
ably because it demonstrated adequate known-groups
validity. The GARS, NHP and SF-36 were tested for
convergent and/or divergent validity and given positive
ratings because the results were in accordance with >
75% of hypotheses. The BI was rated negatively because
it did not correlate strongly with the HAQ (r = 0.42)
and the SIP was correlated only moderately to patient
reported PF (r = 0.41).
For the disease specific scales, no information was
available to rate the construct validity of the FSI, TFCQ
and both versions of the MDHAQ. An indeterminate
ratings was given to the SIP-RA because sub-scale
scores were only being correlated to the total score. Ele-
ven disease specific scales received a positive rating for
construct validity. The AIMS2 and AIMS2-SF were
Table 2 Content validity and measurement properties of included questionnaires
Questionnaire* Relevance Comprehen-
siveness
Construct
validity
Internal
consistency
Test-retest
reliability
Agree-
ment
Respon-
siveness
MIC Ceiling/
floor
effects
Score
distribution
Generic scales
BI [56] - - - ? ? ? ? ? ? ?
GARS [26,57] + + + + ? ? 0 ? ? ?
MHIQ [58] + + + 0 0 ? 0 ? ? ?
NHP [59-63] + - + ? 0 ? 0 ? ? +
SF-36 [64-69] + - + 0 0 0 + + - +
SIP [70-72] - - - ? 0 ? 0 ? ? +
WHODAS-II [73,74] - + 0 0† 0 ? 0 ? - ?
Disease-specific scales
FSI [75] + + ? 0† 0 ? ? ? ? ?
AIMS
[76,77,30,59,78-81]
- + + - 0 ? + ? ? ?
Short AIMS [76] + + + 0† 0 ? 0 ? ? ?
Shortened AIMS [77] + + - 0† 0 ? ? ? ? ?
AIMS2 [82] + + + + 0 ? ? ? ? ?
AIMS2-SF [83] + - + 0 + ? + ? ? ?
CSHQ-RA [28,29,84] - + + + + ? 0 + ? +
CSHQ-RA, revised [27] + + + + + ? 0 + ? +
CSSRD-FAS [85] - + + ? - ? ? ? ? ?
FFbH [86] + - + 0 ? ? 0 ? + ?
HAQ
[40,87,32,41,66,79,88-94]
+ + + + + 0 + + - +
HAQ-II [41] + + + 0 ? ? 0 ? + ?
MDHAQ (10-ADL) [40] + - ? 0 ? ? ? ? + ?
MDHAQ (14-ADL) [40] + + ? 0 ? ? ? ? + ?
MHAQ [40,41,93-95] + - + + 0 0 + ? - +
ROAD [31,96] - + - + + 0 + ? + ?
IRGL [97,98] + + - 0 0 ? ? ? ? ?
TFCQ [99] ? ? ? 0 ? ? ? ? ? ?
SIP-RA [100] - - 0 0 ? ? 0 ? ? ?
+ = good measurement properties with adequate methodological quality; - poor measurement properties with adequate methodological quality; 0 =
indeterminate quality of measurement properties because of inadequate methodological quality; ? = no information found. * For the full names of the
questionnaires see legend of table 1. † No factor analysis was applied, but Cronbach’s a < 0.70.
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rated favourably because respectively known-group com-
parisons and multitrait methods indicated adequate con-
struct validity. The remaining nine scales received
positive ratings because the pattern of correlations was
in sufficient agreement with our hypotheses. Only the
ROAD, IRGL and shortened AIMS were given negative
ratings for construct validity. all of the subscales of the
ROAD were found to be inadequately related to the
HAQ (r = 0.17-0.32), and the SF-36 PF scale (r = 0.18-
0.32). Furthermore, because the scales were generally
weakly related to other measures relevant to our
hypotheses (see supplementary material) eventually only
4 out of 25 (16%) hypotheses were confirmed. For the
IRGL and the shortened AIMS, 65% and 51% of hypoth-
eses were confirmed, respectively.
Internal consistency
For 11 out of 22 questionnaires for which information
on internal consistency was found, factor analysis was
applied before calculating Cronbach’s a. The AIMS was
the only questionnaire to receive a negative rating,
because a < 0.70 was reported for the physical activities
and activities of daily living subscales. The HAQ-II and
SF-36 were rated indeterminate because internal consis-
tency was tested with Rasch analysis and although the
person separation index was deemed acceptable (≥0.70)
in both cases, there was no assessment of the dimen-
sionality of the scales beyond the reporting of item level
fit statistics. The AIMS2-SF and both versions of the
MDHAQ were rated indeterminate because a single
scale was created for PF, while factor analysis had indi-
cated the presence of multiple dimensions. Inappropri-
ate statistical methods were used for the TFCQ, the
sample size was < 50 patients for the MHIQ, and for
the SIP-RA internal consistency analysis was performed
on the total questionnaire scores only, rather than on
individual scales, leading to indeterminate ratings for
these questionnaires as well. For the remaining ques-
tionnaires that were rated indeterminate, factor analysis
had not been applied.
Reproducibility
The HAQ, CSHQ-RA, revised CSHQ-RA, ROAD, and
AIMS2-SF were rated positive for reliability. The NHP,
AIMS, IRGL, and both of the AIMS short forms were
rated indeterminate for reliability because the Pearson
product moment correlation was used instead of the
ICC. The SIP, MHIQ, WHODAS-II, SF-36, AIMS2, and
MHAQ were rated indeterminate because the sample
size was < 50. ICCs for individual items only were
reported for the FSI. Only the CSSRD-FAS received a
negative rating, because ICCs < 0.70 were observed for
the transfer and mobility scales in stable patients.
The LOA or SEM was presented for only four ques-
tionnaires. For the ROAD, the limits of agreement were
not related to the MIC, nor were arguments provided
with respect to the acceptability of the level of agree-
ment between scores on different times. For the HAQ,
MHAQ, and SF-36, the SEM or LOA were estimated in
a sample < 50 patients. Therefore, agreement was rated
indeterminate for all scales.
Responsiveness
Information on responsiveness was found for 17 ques-
tionnaires. Six questionnaires were rated positive for
responsiveness, because either the standardized effect
size or the standardized response mean statistic showed
moderate improvements in scores after effective treat-
ment, with adequate descriptions of contextual factors.
Studies on the GARS, WHODAS-II, and HAQ-II also
utilized appropriate statistics, but their results couldn’t
be interpreted because insufficient information was pre-
sented about the study design or results. Methods that
merely rely on the significance of the difference between
scores at two time points were used for the CSHQ-RA,
revised CSHQ-RA, TFCQ, and short AIMS. These sta-
tistical techniques were considered inadequate because
p-values are inversely related to sample size. For the SIP
and SIP-RA unconventional methods were used to
examine its responsiveness. The remaining scales that
were rated indeterminate had sample sizes < 50 patients.
Interpretability
MICs were reported for four questionnaires. Marked
floor effects were reported for the SF-36, where 22% of
a sample stratified to equally represent patients from all
four Steinbrocker functional classes scored the worst
possible score. However, this was caused almost exclu-
sively by patients in Steinbrocker functional classes III
and IV. Ceiling effects of up to 31% of patients were
reported for the MHAQ, 16% for the HAQ, and > 15%
for the WHODAS-II. For the remaining questionnaires
that were rated, floor and ceiling effects were all well
below the cut-off point of 15%. For seven question-
naires, two or more types of score distributions were
presented that can facilitate the interpretation of ques-
tionnaire scores.
Discussion
This study systematically reviewed the literature on
measurement properties of PF scales that are validated
for use in patients with RA. The results of this review
provide a comprehensive assessment of the available evi-
dence for the utility of available scales for patients with
RA and may inform the appropriate selection of self-
reported PF scales for various purposes in clinical prac-
tice and research.
PROs are commonly classified as disease-specific or
generic. In this systematic review, a pragmatic classifica-
tion was employed based on the intended target popula-
tion of the included questionnaires. However, it should
be noted that although developed for use in arthritic
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populations, PF scales that were classified as disease-
specific do not necessarily have content that is exclu-
sively relevant in these populations. In fact, some scales
such as the HAQ which is often referred to as a disease-
specific measure, assesses physical disability in general
and does not focus on specific disease-associated impair-
ments. As a result, the scale has been used across a wide
range of general and clinical populations [3].
Of the disease-specific scales that were rated positively
for both aspects of validity, the HAQ received the most
favourable overall evaluation. Owing to its longstanding
and extensive use in RA, the measurement properties of
the HAQ have been exhaustively studied. This review
showed that it has predominantly favourable measure-
ment properties that have been studied with adequate
methodological rigor. The HAQ met the standards we
set for responsiveness and its test-retest reliability was
found to be very high in a sample of stable patients,
indicating that the scale is appropriate for evaluative
purposes (i.e., to track physical functioning over time),
both at the group level and at the individual level. How-
ever, one important limitation of the HAQ is that multi-
ple studies noted a considerable group of patients
scoring the best possible score. Therefore, it may not be
the most appropriate scale for use in patient populations
with relatively good functional capacity, since it cannot
measure improvement in a substantial proportion of
patients. Both the MDHAQ (14 ADL) and the HAQ-II
were rated favorably for all aspects of validity as well
and were specifically developed to address the ceiling
effects of the original HAQ [40,41]. Both scales indeed
demonstrated substantially smaller ceiling effects in
direct comparison with the original HAQ, indicating
that these scales might be more appropriate than the
original HAQ for use in relatively well functioning
groups. Another advantage of these scales is that they
contain only 14 and 10 items, making them more feasi-
ble for use in clinical practice or when administering
multiple PROs simultaneously. However, the measure-
ment properties of HAQ-II and MDHAQ (14-ADL)
have been less extensively studied. In particular, before
recommending their use in evaluative studies, the
responsiveness of these scales should be compared to
that of the HAQ and their reproducibility in stable
patients should be established. The revised CSHQ-RA
and AIMS2 were also rated favorably for validity, but no
information is available known about their distributional
properties and the evidence testifying to the responsive-
ness of the revised CSHQ-RA is limited to methods that
rely on statistical significance. Further research is
required before a comprehensive evaluation of the qual-
ity of the revised CSHQ-RA is possible. The AIMS2
might be the most comprehensive disease-specific ques-
tionnaire. Its items were linked to 31 relevant ICF
categories and issues such as fine hand use and arm use
and domestic life are addressed in more detail than in
the HAQ, which was also noted by Stucki et al [14].
However, with its 28 items it is also the most lengthy
questionnaire and much of the work on its measure-
ment properties is outdated. Further psychometric test-
ing is therefore desirable. Finally, the short AIMS was
also rated favorably for all aspect of validity, but it con-
tains scales that lack internal consistency, perhaps
because some subscales consist of only 2 items or
because the response format is often yes/no. Therefore
we would not recommend it for use or for further
testing.
The CSHQ-RA and ROAD are among the most
recently developed disease-specific scales and the meth-
odology of the work on their measurement properties
conforms to the rigorous methodological standards of
COSMIN, enhancing the interpretability of their psycho-
metric quality in this review. Regrettably however, these
scales suffer from irrelevant content. Therefore their use
cannot be recommended for the assessment of PF,
despite generally favorable evaluations for their other
measurement properties.
Although it is well known that measurement proper-
ties are context-specific attributes that can differ across
populations, previous studies have paid no attention to
verifying the content validity of the included generic
scales for use in RA patient groups. Therefore, by link-
ing their content to the comprehensive ICF core set for
RA, this review provides the first assessment of the con-
tent validity of included generic scales for assessing phy-
sical functioning of patients with RA.
The SF-36 PF scale is probably the most frequently
used generic scale in patients with RA. However,
although all of its items are relevant, it measures predo-
minantly mobility and has no content relevant to the
assessment of domestic life, which was already recog-
nized as an important shortcoming by its developers
[42]. Another limitation of the scale is that it has been
associated with substantial floor effects (i.e., patients
scoring the worst possible score). Most of its measure-
ment properties have been studied in patients with RA,
but studies of more rigorous methodological quality are
desirable. For instance, no studies were found reporting
on the dimensionality of the original version and its
reproducibility has been studied in small patient groups
(n < 25) only. On the other hand, the SF-36 PF-10 is
the only generic PF scale that was rated positively for
responsiveness.
Except for the MHIQ, the other health profiles, (SIP
and NHP) demonstrated limited content coverage as
well. Because health profiles intend to cover all major
areas of health, it might be expected that content cover-
age within their components is less comprehensive. The
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GARS on the other hand is a dedicated PF instrument
which is reflected in the finding that its content more
comprehensively reflects the overall PF domain. There-
fore, the GARS may be well suited when the primary
outcome of interest is physical function rather than
overall health. However, as with most generic scales in
this review, its measurement properties are currently
poorly understood. More research is required to estab-
lish its performance in longitudinal settings before its
use can be recommended.
With the inclusion of items of the participation chap-
ters of the ICF, the WHODAS-II covers a wider spec-
trum of disability than just physical function. The same
applies to the BI and SIP. These measures include mul-
tiple items belonging to ICF categories E120 (Products
and technology for personal use in daily living), E30
(support and relationships) and B5253 and B6202 (fecal/
urinary incontinence). Therefore, they might be better
thought of as measures of dependence rather than phy-
sical function per se. This interpretation is further
strengthened by the observation that the SIP and BI
were evaluated negatively for construct validity. In parti-
cular, both scales correlated only moderately with other
PF instruments.
With respect to rating the measurement properties
of the included scales, it was notable that in one-third
of the studies that assessed reliability, samples of less
than 25 patients were used. Although observed ICCs
were generally well above the commonly accepted cut-
off point of 0.70, it is important that reliability is stu-
died in sufficiently large samples. Simulation studies
have shown that even when a value as high as 0.80 is
observed, a sample size of 60 patients is required to
reliably conclude that ICC > 0.70 in the population the
sample was drawn from [43,44]. Furthermore, for most
scales, information on reproducibility of scores was
limited to reports on test-retest reliability. For evalua-
tive purposes, especially when monitoring functional
status of individual patients, it is informative to report
on the absolute agreement of test-retest scores for
patients with unchanged functional status as well.
Representative values of the LOA or SEM can serve as
benchmarks for distinguishing real change in func-
tional status from changes due to random measure-
ment error [17]. Finally, minimally important change
scores have not been widely reported and should be
addressed in future research, as they greatly enhance
the interpretability of change scores. Instruments
should be administered longitudinally before and after
treatment known to improve PF, and health transition
questions should be included as external criteria of
change (26). A point worth mentioning is that this sys-
tematic review is limited to traditional static
questionnaires.
Recently, item response theory (IRT) based item bank-
ing is receiving increasing attention in PRO assessment.
Of special relevance to PF assessment in RA populations
is the patient reported outcome measurement informa-
tion system (PROMIS) initiative. PROMIS is an NIH
initiative aimed at revising instruments in many
domains including PF, using IRT calibrations and com-
puterized adaptive testing (CAT) [45]. The PROMIS PF
item bank contains 124 calibrated items and CAT algo-
rithms allow for the adaptive selection of the most rele-
vant item for a particular patient in terms of relative
difficulty based on previous answers given by that
patient [46]. The main advantage of using these modern
psychometric approaches is that the use of extensive
item banks potentially eliminates floor and ceiling
effects, while the CAT algorithm ensures that patients
only need to answer a minimum number of questions
[47,48]. Short forms can also be developed from the
PROMIS item banks. For example, the PROMIS HAQ
has been developed from the PROMIS PF item bank
[46]. Unfortunately, none of the PROMIS studies met
the inclusion criteria for this review of at least 50% RA
patients, however the PROMIS PF item bank is likely to
become a prominent measurement system in RA and it
would be highly interesting for future research to study
the psychometric properties of the PROMIS PF item
bank specifically for RA populations.
There are some limitations to our study that deserve
attention. First, we used the ICF as an external standard
to evaluate the content validity of the included scales, as
have a number of previous similar systematic reviews
[49,50]. The ICF aims to provide a common language
for functional status assessment in clinical practice and
research. However, most included scales were developed
before the ICF was available. Moreover, concerns have
been voiced regarding the exhaustiveness of the ICF as a
comprehensive classification of disability [51] and sev-
eral validation studies of the ICF core set for RA have
found some omissions from the perspective of patients
and physicians that future research should address
[52,53]. Therefore some caution must be taken when
interpreting the results of the analysis of content valid-
ity. Still, the ICF is frequently recommended for asses-
sing the content validity of health status instruments
[15] and 95% of all PF items included in this systematic
review could be linked to at least one ICF code. More-
over, the items that were linked to ICF categories other
than mobility, self-care or domestic life were all clearly
irrelevant to the assessment of PF. Our results therefore
seem to indicate that the ICF is a useful taxonomic tool
for assessing the relevance of disability items, such as
those included in this systematic review. Second, for
most scales, the work on their measurement properties
was predominantly or exclusively performed with the
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original language versions. However, the majority of the
studies on the measurement properties of the AIMS2
and AIMS2-SF concerned translated versions. Users of
translated versions are therefore advised to examine if a
validation study is available for their language version,
rather than solely depending on the results of this
review. For several translations, individual items were
omitted, changed, or added in order to adapt a ques-
tionnaire for use in a different culture. Since in some
instances up to 10% of items were changed, it is unclear
to what degree measurement properties are generaliz-
able across versions and cultures [54,55].
Conclusions
None of the scales met all the rigorous quality require-
ments we set. However the disease-specific HAQ can
confidently be recommended for most applications in
patients with RA. Longitudinal or experimental studies
in patient groups with relatively good functional capacity
may require scales with broader measurement range
such as the MDHAQ (14 ADL) or HAQ-II. However,
since their longitudinal performance is currently poorly
documented, their test-retest reliability and responsive-
ness should be addressed by future research first. The
SF-36 is the most thoroughly evaluated generic scale
that is currently most suited for studies that want to
compare RA patients with other populations. In particu-
lar, it is the only generic scale with adequate proven
responsiveness. However it has limited coverage of the
PF domain and therefore it would be desirable to com-
pare its performance in longitudinal settings with that of
the GARS and MHIQ, which more comprehensively
measure PF.
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